|
Fetal Alcohol Syndrome
|
0.500 |
Biomarker
|
disease |
CTD_human |
Importance of genetics in fetal alcohol effects: null mutation of the nNOS gene worsens alcohol-induced cerebellar neuronal losses and behavioral deficits.
|
25511929 |
2015 |
|
Fetal Alcohol Syndrome
|
0.500 |
Biomarker
|
disease |
PSYGENET |
Importance of genetics in fetal alcohol effects: null mutation of the nNOS gene worsens alcohol-induced cerebellar neuronal losses and behavioral deficits.
|
25511929 |
2015 |
|
Hyperalgesia
|
0.500 |
Biomarker
|
phenotype |
RGD |
These effects were associated with decreased up-regulation of neuronal NOS (nNOS), CGRP and c-Fos expression in the spinal dorsal horn and/or DRG.However, i.t. administration of CTAP blocked the induction by BAM8-22 of delayed anti-hyperalgesia and inhibition of nNOS and CGRP expression in DRG.
|
23909597 |
2013 |
|
Hepatic Encephalopathy
|
0.500 |
Biomarker
|
disease |
RGD |
Induction of NOS and nitrotyrosine expression in the rat striatum following experimental hepatic encephalopathy.
|
19763802 |
2009 |
|
Hyperalgesia
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
|
19300402 |
2009 |
|
Hepatic Encephalopathy
|
0.500 |
Biomarker
|
disease |
RGD |
The expression of nNOS, iNOS and nitrotyrosine is increased in the rat cerebral cortex in experimental hepatic encephalopathy.
|
17083474 |
2006 |
|
Hepatic Encephalopathy
|
0.500 |
Biomarker
|
disease |
CTD_human |
Hepatic encephalopathy: An update of pathophysiologic mechanisms.
|
10564534 |
1999 |
|
Hepatic Encephalopathy
|
0.500 |
Biomarker
|
disease |
CTD_human |
Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy.
|
10206825 |
1998 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the suppression of nNOS enzyme by targeted siRNAs modified the progressive death of dopaminergic cells induced by 6-OHDA and merits further pre-clinical investigations as a neuroprotective approach for PD.
|
31041676 |
2019 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
While nNOS exon 29 TT variant genotype [odds ratio (OR) = 2.20, 95 % CI = 1.08-5.34, P = 0.040], combined TT and CT variants [OR = 1.68, 95 % CI = 1.05-2.69, P = 0.031] and T allele [OR = 1.58, 95 % CI = 1.10-2.28, P = 0.014] were found to be significantly associated with PD susceptibility, no association between nNOS exon 18 [OR for TT carriers = 1.97, 95 % CI = 0.89-4.20, P = 0.09 and OR for T allele = 1.35, 95 % CI = 0.94-1.93, P = 0.098] and PD risk was observed.
|
26081147 |
2016 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The analysis results indicated that NOS1 exon18 polymorphism was associated with developing PD in 4 genetic models (allelic: OR = 1.25, 95%CI 1.09-1.44, P = 0.001; homozygous: OR = 1.79, 95%CI 1.32-2.45, P < 0.001; recessive: OR = 1.70, 95%CI 1.26-2.28, P < 0.001; dominant: OR = 1.22, 95%CI 1.02-1.46, P = 0.03), whereas exon29 polymorphism was not correlated to PD susceptibility.
|
27749554 |
2016 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Here, we investigated contributions of NOS genes and OP pesticides to PD risk, controlling for PON1 status.
|
26383258 |
2016 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we investigated contributions of NOS genes and OP pesticides to PD risk, controlling for PON1 status.
|
26383258 |
2016 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The polymorphism's length has been suggested to affect NOS1 transcription and play a role in Parkinson's disease (PD); however, the actual influence of the polymorphism on NOS1 transcription has not been studied.
|
19326438 |
2009 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data implicate NOS1 and NOS2A as genetic risk factors for PD and demonstrate that their interactions with established environmental factors may modulate the environmental effects.
|
18663495 |
2008 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This review mainly focuses on the NOS genes - their differential regulation and genetic heterogeneity, highlighting their significance in the pathobiology of PD.
|
16934505 |
2006 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Other studies reported that smoking modified the risk of PD due to polymorphisms in the MAO-B and nNOS genes.
|
15699372 |
2005 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, inhibition of two NO-synthesizing enzymes, neuronal NOS (nNOS) and inducible NOS (iNOS), displays neuroprotective effects in the MPTP model of Parkinson's disease (PD).
|
12490535 |
2003 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine if NOS gene polymorphism affects the 5' flanking region that is immediately upstream of the transcription start site lying between the TATA element and CAATT boxes in PD, and differs significantly between patients with PD and normal controls, we studied genetic polymorphism in that region of the neuronal NOS gene in Chinese patients with PD living in Taiwan.
|
11809160 |
2002 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Quantitation of SS mRNA expression on emulsion dipped sections revealed a significant increase (82%) in the MML of the globus pallidus in PD (56.5 microm2 of silver grain/cell, n = 9 cases) compared to controls (26.3 microm2/cell, n = 13 cases, p < 0.01, Student's t-test), paralleling the increase previously observed by this group for NOS mRNA.
|
9406918 |
1997 |
|
Depressive disorder
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that cyclic AMP-dependent protein kinase (PKA) phosphorylates neuronal nitric oxide synthase (nNOS) at Ser<sup>1412</sup> in the hippocampal dentate gyrus after forebrain ischemia; this phosphorylation event activates NOS activity and might contribute to depression after cerebral ischemia.
|
29074292 |
2018 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
Evidence has shown that single nucleotide polymorphisms located in pre‑microRNA (miRNA) or mature miRNA may modify various biological processes and affect the process of carcinogenesis, and the downregulation of neuronal nitric oxide synthase 1 (NOS1) can induce depression.
|
29749487 |
2018 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the association between single-nucleotide polymorphisms of the genes encoding SOD2 (superoxide dismutase 2), CAT (catalase), GPx4 (glutathione peroxidase 4), NOS1 (nitric oxide synthase 1), NOS2 (nitric oxide synthase 2), and the development of depressive disorders.
|
29331597 |
2018 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression.
|
27977470 |
2017 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
These results suggest that NOS1 SNPs interact with exposure to economic and psychosocial stressors to alter individual's susceptibility to depression.
|
24917196 |
2014 |